ANA/ENA 18 Antigens, Qualitative Profile, Blot/LIA near me in Trimulgherry

The SS-B/La measures the presence of antibodies against the SS-B antigen in the blood. These antibodies are often associated with autoimmune disorders, particularly Sjorgen's syndrome. This test is used alongside SS-A (Ro) antibody test to help in the diagnosis of Sjogren's syndrome and other autoimmune diseases like Systemic lupus erythematosus (SLE). Detecting SS-B antibodies helps doctors assess autoimmune activity, confirm diagnosis and differentiate between various autoimmune conditions. However, the presence of SS-B antibodies alone is not definitive, and results should be interpreted in conjunction with clinical symptoms and other laboratory findings.

The ds-DNA test detects the presence of antibodies specifically directed against the genetic material called double-stranded DNA (dsDNA) found in the nucleus of cells. These antibodies are often found in systemic lupus erythematosus (SLE), an autoimmune disease where the immune system mistakenly attacks its own DNA. A positive result means that these antibodies are present, suggesting active disease or flare-ups, especially in the kidneys. A negative result means the antibodies were not found, making SLE less likely but not ruling it out completely. This test helps doctors understand if the disease is active and monitor how well treatments are working.

The SmD1 test detects the presence of anti-Sm antibodies, often found in individuals with systemic lupus erythematosus (SLE), a type of autoimmune disease. The SmD1 test specifically helps doctors diagnose lupus, as these antibodies are highly specific to the disease. A positive result for anti-SmD1 antibodies, along with other clinical signs and symptoms, may help confirm the diagnosis of SLE. However, not everyone with lupus will have these antibodies, and they can sometimes be present in other conditions. On the other hand, a negative result means that these specific antibodies were not detected in the blood. While a negative result makes SLE less likely, it doesn't completely rule it out, as some individuals with lupus may not have detectable anti-Sm antibodies. 

The PCNA, (Proliferating Cell Nuclear Antigen) test detects antibodies against PCNA, a protein that plays a key role in DNA replication and repair. These antibodies are a rare type of antinuclear antibodies (ANA), considered highly specific for systemic lupus erythematosus (SLE), and connective tissue disorders but can also be found in viral infections, or tumors. A positive result for PCNA antibodies may suggest the presence of these autoimmune conditions. A negative result in the PCNA test means that no antibodies against the PCNA protein were detected in the blood suggesting a lower likelihood of autoimmune diseases. However, the test is not used alone for diagnosis and is typically considered alongside other clinical findings and tests to help confirm an autoimmune disorder.

The P0 (RPP), also known as the Ribosome P Protein antibody test, checks for antibodies that attack the P0, P1, and P2 proteins found in the 60S subunit of the ribosome. These proteins are important for making proteins inside cells. The presence of these antibodies is often seen in people with Systemic Lupus Erythematosus (SLE), especially those with neuropsychiatric symptoms like depression, confusion, or psychosis. The test is helpful for diagnosing neuropsychiatric lupus and can also indicate kidney problems in lupus patients.  A positive result suggests the presence of antibodies commonly associated with Systemic Lupus Erythematosus (SLE), while a negative result typically means these specific antibodies are not present, though it doesn’t rule out lupus or other conditions.

The (test_name), also Anti-Dense Fine Speckled Protein 70 (Anti-DFS70) test detects antibodies targeting the DFS70 protein in the blood. These antibodies are often linked to autoimmune disorders, such as Systemic Lupus Erythematosus (SLE) or Sjögren's Syndrome. However, Anti-DFS70 antibodies can also appear in healthy individuals. This test is useful in identifying individuals who do not have an ANA-associated Autoimmune Rheumatic Disease (AARD), particularly when there are no significant clinical symptoms. When Anti-DFS70 antibodies are positive in isolation (without other AARD-associated antibodies), it can help prevent unnecessary tests for individuals who test positive for ANA but do not have an autoimmune condition.

The Ku antibody test is used to detect antibodies against the Ku protein, which is involved in DNA repair and other cellular processes. These antibodies are associated with certain autoimmune diseases, particularly systemic sclerosis, polymyositis and overlap syndrome such as MIxed Connective tissues disease( MCTD). This test is not commonly prescribed as other autoimmune tests but it is useful in diagnosing and differentiating between autoimmune conditions when patients presents with overlapping symptoms like muscle weakness, joint inflammation etc. The presence of Ku antibodies, along with clinical findings and other laboratory tests, helps doctors tailor treatment plans and better understand the patient's autoimmune profile.

The Mi-2 test checks for the presence of autoantibodies that target the Mi-2 nuclear antigen, a protein involved in gene regulation and muscle function. This test is used to help diagnose idiopathic inflammatory myopathies, such as Dermatomyositis (DM) and Polymyositis (PM), which are autoimmune diseases that cause muscle weakness and skin rashes. A positive result indicates the presence of Mi-2 antibodies, suggesting one of these conditions. A negative result means that the antibodies are not found, making these diseases less likely, but it doesn't completely rule them out. Additional tests may be needed for a more accurate diagnosis.

The Scl-70 test detects the presence of antibodies against the topoisomerase I enzyme, which plays a role in DNA replication and repair. The presence of these antibodies are associated with systemic sclerosis (SSc), also known as scleroderma. The test can help diagnose SSc, predict the risk of complications, and differentiate SSc from other similar autoimmune conditions. A positive test result suggests that the immune system may be attacking this enzyme, which can lead to tissue damage and fibrosis. A negative result typically means that these antibodies are not present, making systemic sclerosis less likely, though it doesn’t completely rule it out. Additional tests may be needed to confirm a diagnosis or explore other possible autoimmune conditions.

The PM-Scl test is used to detect antibodies against PM-Scl proteins, which are involved in the regulation of RNA and protein synthesis within cells. This test is primarily used to help diagnose Polymyositis (PM) and Systemic Sclerosis (SSc), specifically a form known as overlap syndrome, where symptoms of both diseases occur together. A positive result suggests the presence of these antibodies, which can indicate an autoimmune response affecting muscles, skin, and internal organs. A negative result means the antibodies are not detected, making these conditions less likely, though it doesn’t entirely rule them out. Additional tests may be needed to confirm the diagnosis or consider other autoimmune diseases.

The Jo-1 test is used to detect antibodies against the JO-1 protein, which plays a role in muscle and tissue function. Jo-1 antibody is a myositis-specific autoantibody most commonly found in patients with idiopathic inflammatory myopathies (IIM). This test is primarily used to help diagnose IIM, particularly Dermatomyositis (DM) and Polymyositis (PM). It can be considered a specific marker of IIM, predominantly found in these conditions. The test is also associated with Interstitial Lung Disease (ILD), Raynaud phenomenon, arthritis, and mechanic's hands. A positive result suggests the presence of anti-synthetase syndrome (a rare autoimmune disease that affects multiple systems of the body) or a higher risk of myositis (muscle inflammation). A negative result means the antibodies are not detected, but it does not completely rule out the diagnosis of idiopathic inflammatory myositis. Further tests may be needed for a definitive diagnosis.

The Histones test is used to detect antibodies against histones, which are proteins that help package DNA within cells. This test is primarily used to help diagnose drug-induced lupus, a form of lupus that is triggered by certain medications. The test can also be helpful in diagnosing Systemic Lupus Erythematosus (SLE), although it is more commonly seen in drug-induced lupus. A positive result suggests the presence of antibodies against histones, which can indicate an autoimmune response, often associated with lupus. A negative result means that histone antibodies are not detected, making drug-induced lupus or lupus less likely, though it doesn't completely rule out the condition. Further tests may be needed for a more accurate diagnosis.

The CENP-B, also known as Centromere Protein B test is used to detect antibodies against the centromere protein CENP-B in the blood. This protein plays a role in cell division and is associated with certain autoimmune disorders. The test is primarily used to diagnose Systemic Sclerosis (SSc), including its specific form known as CREST syndrome (Limited Systemic Sclerosis). A positive result suggests the presence of these antibodies, helping doctors confirm a diagnosis of scleroderma or CREST syndrome. A negative result means that these antibodies are not found, making these conditions less likely, but it doesn't completely rule them out. In some cases, further testing may be needed to confirm the diagnosis.

The Nucleosomes test detects the presence or absence of antibodies against nucleosomes, which are structures made of DNA and proteins found in the nucleus of cells. These antibodies are often linked to autoimmune diseases, especially systemic lupus erythematosus (SLE) and drug-induced lupus. A positive result means that these antibodies are present in the blood, which may indicate an autoimmune response. A negative result in the qualitative nucleosome test means that no antibodies against nucleosomes were detected in the blood. This suggests that the person is less likely to have an autoimmune disease. However, it doesn't completely rule out other autoimmune conditions or the possibility of the disease developing later. 

The U1-snRNP, also known as (U1 small nuclear ribonucleoprotein) test is used to detect antibodies against the U1-snRNP, a group of proteins involved in the process of RNA splicing, which is essential for proper cell function. This test helps diagnose rheumatic diseases such as mixed connective tissue disease (MCTD), and systemic lupus erythematosus (SLE). This test also helps doctors differentiate MCTD from other similar illnesses, making it easier to understand the specifics of the autoimmune response. A positive result suggests that the immune system may be attacking these proteins, leading to inflammation and potential tissue damage. The U1-snRNP test is often used when a doctor suspects an autoimmune disease and needs more specific information to confirm the diagnosis. 

The AMA-M2 test detects the presence of anti-mitochondrial antibodies (AMAs) that play a critical role in the context of primary biliary cholangitis (PBC), a chronic liver disease. These autoantibodies target specific proteins in the mitochondria and are found in approximately 95% of individuals suffering from PBC, making them highly specific for the disease. A positive AMA-M2 test result suggests that the body is producing antibodies against these mitochondrial proteins, which can help confirm a PBC diagnosis. On the other hand, a negative result generally indicates that PBC is unlikely, although it doesn't completely rule out other liver conditions.